Calidi Biotherapeutics, Inc.
CLDI
$1.36
$0.010.74%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.27% | -1.28% | 21.23% | 9.90% | -14.62% |
| Total Depreciation and Amortization | 2.82% | 0.71% | -0.94% | 4.91% | 3.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.66% | 56.41% | -80.40% | 20.61% | -0.20% |
| Change in Net Operating Assets | -27.88% | 59.62% | -1,252.21% | -68.66% | 97.79% |
| Cash from Operations | -5.76% | 18.40% | -19.02% | 13.16% | 31.57% |
| Capital Expenditure | -560.00% | 82.76% | -7.41% | 52.63% | -714.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -560.00% | 93.67% | -192.59% | 52.63% | -714.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.82% | -62.96% | 93.32% | -3.06% | 76.48% |
| Issuance of Common Stock | -62.90% | 1,001.23% | -91.99% | 202,966.67% | -99.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.99% | -41.32% | -103.19% | 4,840.00% | 73.42% |
| Cash from Financing | -64.55% | 1,417.35% | -96.41% | 2,121.32% | -105.78% |
| Foreign Exchange rate Adjustments | 57.14% | -187.50% | -- | -100.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -348.30% | 121.59% | -191.56% | 196.57% | -656.70% |